ERYTECH Pharma announces the oral presentation of very demonstrative results regarding its technology to Induce specific immune tolerance by antigen loaded erythrocytes. admERY September 7, 2012 Newsroom You Might Also Like ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 September 21, 2020 ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer April 28, 2020 ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting December 8, 2015
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 September 21, 2020
ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer April 28, 2020
ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting December 8, 2015
